ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,012.28
-1.46%
Dow Jones
44,713.58
0.65%
US Dollar vs MXN
20.68055
-0.31%
Brent Oil
76.465
0.26%
Bitcoin
102,879.12
0.79%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immutep Ltd (IMMP)

  7. Immutep Ltd (IMMP) Noticias

IMMP

Immutep (IMMP)

Immutep Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMMP
FechaHoraFuenteTítuloSímboloCompañía
22/01/202507:00GlobeNewswire Inc.Patient Enrolment Completed for EFTISARC-NEO Phase II TrialNASDAQ:IMMPImmutep Ltd
06/01/202507:00GlobeNewswire Inc.Patient Enrolment Completed for INSIGHT-003NASDAQ:IMMPImmutep Ltd
17/12/202407:00GlobeNewswire Inc.Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761NASDAQ:IMMPImmutep Ltd
16/12/202407:00GlobeNewswire Inc.Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IINASDAQ:IMMPImmutep Ltd
12/12/202414:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMMPImmutep Ltd
12/12/202407:15GlobeNewswire Inc.Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024NASDAQ:IMMPImmutep Ltd
10/12/202407:00GlobeNewswire Inc.Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
14/11/202407:15GlobeNewswire Inc.Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
14/11/202407:00GlobeNewswire Inc.Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual MeetingNASDAQ:IMMPImmutep Ltd
29/10/202407:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q1 FY25NASDAQ:IMMPImmutep Ltd
28/10/202407:00GlobeNewswire Inc.Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024NASDAQ:IMMPImmutep Ltd
17/10/202407:00GlobeNewswire Inc.Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of TrialNASDAQ:IMMPImmutep Ltd
10/10/202407:00GlobeNewswire Inc.Immutep to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:IMMPImmutep Ltd
03/10/202407:00GlobeNewswire Inc.Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerNASDAQ:IMMPImmutep Ltd
24/09/202407:00GlobeNewswire Inc.Immutep Receives A$3.6 million R&D Tax Incentive from French GovernmentNASDAQ:IMMPImmutep Ltd
18/09/202407:00GlobeNewswire Inc.New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
16/09/202407:00GlobeNewswire Inc.Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck CancerNASDAQ:IMMPImmutep Ltd
20/08/202407:00GlobeNewswire Inc.Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024NASDAQ:IMMPImmutep Ltd
14/08/202407:00GlobeNewswire Inc.Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 AntibodyNASDAQ:IMMPImmutep Ltd
07/08/202407:00GlobeNewswire Inc.Immutep to Participate in Upcoming Investor ConferencesNASDAQ:IMMPImmutep Ltd
31/07/202407:00GlobeNewswire Inc.Immutep Quarterly Activities Report Q4 FY24NASDAQ:IMMPImmutep Ltd
22/07/202407:00GlobeNewswire Inc.Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung CancerNASDAQ:IMMPImmutep Ltd
17/07/202407:00GlobeNewswire Inc.Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune DiseasesNASDAQ:IMMPImmutep Ltd
11/07/202417:40GlobeNewswire Inc.Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 ExpressionNASDAQ:IMMPImmutep Ltd
03/07/202407:00GlobeNewswire Inc.Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical ResultsNASDAQ:IMMPImmutep Ltd
25/06/202407:00GlobeNewswire Inc.Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for CancerNASDAQ:IMMPImmutep Ltd
05/06/202405:00GlobeNewswire Inc.Immutep successfully completes institutional placement and institutional component of entitlement offerNASDAQ:IMMPImmutep Ltd
02/06/202419:38GlobeNewswire Inc.Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III TrialNASDAQ:IMMPImmutep Ltd
15/05/202407:00GlobeNewswire Inc.Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024NASDAQ:IMMPImmutep Ltd
02/05/202407:00GlobeNewswire Inc.Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaNASDAQ:IMMPImmutep Ltd
 Showing the most relevant articles for your search:NASDAQ:IMMP

Su Consulta Reciente

COIN
DOGEUSD
Dogecoin
NYSE
MCD
McDonalds
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
GOOGL
Alphabet
NYSE
DIS
Walt Disney
COIN
ADAUSD
Cardano
NYSE
NKE
Nike
AMEX
SPY
SPDR S&P 500
NASDAQ
AMZN
Amazon.com
NASDAQ
MSFT
Microsoft
USOTC
DTEGY
Deutsche Telekom (QX)
USOTC
RHHBY
Roche (QX)
FX
USDMXN
US Dollar vs MXN
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados